Finasteride | CAS# 98319-26-7 | type II and type III 5α-reductase inhibitor

Finasteride
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317872

CAS#: 98319-26-7

Description: Finasteride is a medication used for the treatment of benign prostatic hyperplasia (BPH) and male pattern baldness (MPB). It is a type II and type III 5α-reductase inhibitor; 5α-reductase, an enzyme, converts testosterone to dihydrotestosterone (DHT).

Chemical Structure

Finasteride

CAS# 98319-26-7

Product data Instruction

Theoretical Analysis

MedKoo Cat#: 317872
Name: Finasteride
CAS#: 98319-26-7
Chemical Formula: C23H36N2O2
Exact Mass: 372.28
Molecular Weight: 372.544
Elemental Analysis: C, 74.15; H, 9.74; N, 7.52; O, 8.59

Price and Availability

Size	Price	Availability
100mg	USD 90	Ready to ship
200mg	USD 150	Ready to ship
500mg	USD 300	Ready to ship
1g	USD 500	Ready to ship
2g	USD 850	Ready to ship
5g	USD 1650	Ready to ship
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: Finasteride, Proscar, Eucoprost, Propecia, MK 906

IUPAC/Chemical Name: (4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-(tert-butyl)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide

InChi Key: DBEPLOCGEIEOCV-WSBQPABSSA-N

InChi Code: InChI=1S/C23H36N2O2/c1-21(2,3)25-20(27)17-8-7-15-14-6-9-18-23(5,13-11-19(26)24-18)16(14)10-12-22(15,17)4/h11,13-18H,6-10,12H2,1-5H3,(H,24,26)(H,25,27)/t14-,15-,16-,17+,18+,22-,23+/m0/s1

SMILES Code: C[C@]12CC[C@H]3[C@@H](CC[C@@H]4[C@]3(C)C=CC(N4)=O)[C@@H]1CC[C@@H]2C(NC(C)(C)C)=O

Appearance: Solid powder

Purity: >97% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Product Data:

Product Data

Certificate of Analysis:

View CoA: current batch, Lot#C22B12B15

Safety Data Sheet (SDS):

View Safety Data Sheet (SDS)

Instruction:

View handling instruction

Biological target:	Finasteride (MK-906) is a potent, reversible inhibitor of the rat type 1 5 alpha-reductase with Ki of 10.2 nM, used in the treatment of benign prostatic hyperplasia (BPH) and male pattern baldness (MPB).
In vitro activity:	It was observed that treatment of finasteride did not affect the growth of androgen-refractory PC-3 prostate cancer cells. Finasteride also failed to induce apoptosis or affect the expression of proto-oncogenes in PC-3 cells. Interestingly, it was found that treatment of finasteride induced the expression of Nrf2 and HO-1 proteins in PC-3 cells. In particular, basal level of Nrf2 protein was higher in androgen-refractory prostate cancer cells, e.g. DU-145 and PC-3 cells, compared with androgen-responsive prostate cancer cells, e.g. LNCaP cells. Also, treatment of finasteride resulted in a selective induction of Nrf2 protein in DU-145 and PC-3 cells, but not in LNCaP cells. In view of the fact that upregulation of Nrf2-mediated phase II cytoprotective enzymes contribute to attenuating tumor promotion in normal cells, but, on the other hand, confers a selective advantage for cancer cells to proliferate and survive against chemical carcinogenesis and other forms of toxicity, it’s proposed that finasteride-mediated induction of Nrf2 protein might be responsible, at least in part, for an increased risk of high-grade prostate tumor formation in men. Reference: Biomol Ther (Seoul). 2013 Jan;21(1):49-53. https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24009858/
In vivo activity:	Five dogs were treated with finasteride for 16 weeks (0.1 to 0.5 mg/kg [0.05 to 0.23 mg/lb] of body weight, PO, q 24 h); the other 4 received a placebo. Prostatic diameter, measured radiographically, prostatic volume, measured ultrasonographically, semen quality, and serum DHT and testosterone concentrations were evaluated before and during treatment. After receiving the placebo for 16 weeks, the 4 control dogs were treated with finasteride for 16 weeks, and evaluations were repeated. Finasteride significantly decreased prostatic diameter (mean percentage decrease, 20%), prostatic volume (mean percentage decrease, 43%), and serum DHT concentration (mean percentage decrease, 58%). Finasteride decreased semen volume but did not adversely effect semen quality or serum testosterone concentration. No adverse effects were reported by owners of dogs in the study. Reference: J Am Vet Med Assoc. 2001 Apr 15;218(8):1275-80. https://avmajournals.avma.org/doi/10.2460/javma.2001.218.1275?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

Solubility Data

	Solvent	Max Conc. mg/mL	Max Conc. mM
Solubility
	DMSO	150.0	402.64
	Ethanol	75.0	201.32

Preparing Stock Solutions

The following data is based on the product molecular weight 372.54 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:	1. Yun DK, Lee J, Keum YS. Finasteride Increases the Expression of Hemoxygenase-1 (HO-1) and NF-E2-Related Factor-2 (Nrf2) Proteins in PC-3 Cells: Implication of Finasteride-Mediated High-Grade Prostate Tumor Occurrence. Biomol Ther (Seoul). 2013 Jan;21(1):49-53. doi: 10.4062/biomolther.2012.080. PMID: 24009858; PMCID: PMC3762299.
In vivo protocol:	1. Sirinarumitr K, Johnston SD, Kustritz MV, Johnston GR, Sarkar DK, Memon MA. Effects of finasteride on size of the prostate gland and semen quality in dogs with benign prostatic hypertrophy. J Am Vet Med Assoc. 2001 Apr 15;218(8):1275-80. doi: 10.2460/javma.2001.218.1275. PMID: 11330612.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Elkelany OO, Owen RC, Kim ED. Combination of tadalafil and finasteride for improving the symptoms of benign prostatic hyperplasia: critical appraisal and patient focus. Ther Clin Risk Manag. 2015 Mar 30;11:507-13. doi: 10.2147/TCRM.S80353. eCollection 2015. Review. PubMed PMID: 25848297; PubMed Central PMCID: PMC4386768.

2: Gupta AK, Charrette A. The efficacy and safety of 5α-reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit-risk assessment of finasteride and dutasteride. J Dermatolog Treat. 2014 Apr;25(2):156-61. doi: 10.3109/09546634.2013.813011. Epub 2013 Jul 5. Review. PubMed PMID: 23768246.

3: Boychenko O, Bernstein RM, Schweiger ES. Finasteride in the treatment of female pattern (androgenic) alopecia: a case report and review of the literature. Cutis. 2012 Aug;90(2):73-6. Review. PubMed PMID: 22988650.

4: Berthold D, Lhermitte B, Uffer M, Doerfler A. Finasteride-related Leydig cell tumour: report of a case and literature review. Andrologia. 2012 May;44 Suppl 1:836-7. doi: 10.1111/j.1439-0272.2011.01214.x. Epub 2011 Sep 26. Review. PubMed PMID: 21950360.

5: Krome S. [How effective is finasteride?]. Dtsch Med Wochenschr. 2011 Feb;136(8):354. doi: 10.1055/s-0031-1275154. Epub 2011 Feb 23. Review. German. PubMed PMID: 21348003.

6: Hulin-Curtis SL, Petit D, Figg WD, Hsing AW, Reichardt JK. Finasteride metabolism and pharmacogenetics: new approaches to personalized prevention of prostate cancer. Future Oncol. 2010 Dec;6(12):1897-913. doi: 10.2217/fon.10.149. Review. PubMed PMID: 21142863.

7: Mella JM, Perret MC, Manzotti M, Catalano HN, Guyatt G. Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review. Arch Dermatol. 2010 Oct;146(10):1141-50. doi: 10.1001/archdermatol.2010.256. Review. PubMed PMID: 20956649.

8: Tacklind J, Fink HA, Macdonald R, Rutks I, Wilt TJ. Finasteride for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2010 Oct 6;(10):CD006015. doi: 10.1002/14651858.CD006015.pub3. Review. PubMed PMID: 20927745.

9: Lynn R, Krunic A. Therapeutic hotline. Treatment of androgenic alopecia with finasteride may result in a high grade prostate cancer in patients: fact or fiction? Dermatol Ther. 2010 Sep-Oct;23(5):544-6. doi: 10.1111/j.1529-8019.2010.01358.x. Review. PubMed PMID: 20868409.

10: Chaudhary UB, Turner JS. Finasteride. Expert Opin Drug Metab Toxicol. 2010 Jul;6(7):873-81. doi: 10.1517/17425255.2010.495944. Review. PubMed PMID: 20536414.

11: Stout SM, Stumpf JL. Finasteride treatment of hair loss in women. Ann Pharmacother. 2010 Jun;44(6):1090-7. doi: 10.1345/aph.1M591. Epub 2010 May 4. Review. PubMed PMID: 20442354.

12: Lebdai S, Bigot P, Azzouzi AR. High-grade prostate cancer and finasteride. BJU Int. 2010 Feb;105(4):456-9. doi: 10.1111/j.1464-410X.2009.09089.x. Epub 2009 Nov 20. Review. PubMed PMID: 19930174.

13: Li J, Kim J. Molecular profiles of finasteride effects on prostate carcinogenesis. Cancer Prev Res (Phila). 2009 Jun;2(6):518-24. doi: 10.1158/1940-6207.CAPR-08-0241. Epub 2009 Jun 2. Review. PubMed PMID: 19491289.

14: De Nunzio C, Miano R, Trucchi A, Finazzi Agrò E, Tubaro A. Finasteride for prostatic disease: an updated and comprehensive review. Expert Opin Drug Metab Toxicol. 2008 Dec;4(12):1561-8. doi: 10.1517/17425250802587058 . Review. PubMed PMID: 19040331.

15: Bhardwa J, Goldstraw M, Tzortzis S, Kirby R. Finasteride and doxazosin alone or in combination for the treatment of benign prostatic hyperplasia. Expert Opin Pharmacother. 2007 Jun;8(9):1337-44. Review. PubMed PMID: 17563267.

16: D'Amico AV, Barry MJ. Prostate cancer prevention and finasteride. J Urol. 2006 Nov;176(5):2010-2; discussion 2012-3. Review. PubMed PMID: 17070238.

17: Fleshner N, Kulkarni G. Should finasteride be used to prevent prostate cancer? Curr Treat Options Oncol. 2006 Sep;7(5):346-54. Review. PubMed PMID: 16904051.

18: Goetzl MA, Holzbeierlein JM. Finasteride as a chemopreventive agent in prostate cancer: impact of the PCPT on urologic practice. Nat Clin Pract Urol. 2006 Aug;3(8):422-9. Review. PubMed PMID: 16902518.

19: Finn DA, Beadles-Bohling AS, Beckley EH, Ford MM, Gililland KR, Gorin-Meyer RE, Wiren KM. A new look at the 5alpha-reductase inhibitor finasteride. CNS Drug Rev. 2006 Spring;12(1):53-76. Review. PubMed PMID: 16834758.

20: Canby-Hagino ED, Brand TC, Hernandez J, Thompson IM. Chemoprevention of prostate cancer with finasteride. Expert Opin Pharmacother. 2006 May;7(7):899-905. Review. PubMed PMID: 16634712.

Your view history

Finasteride featured